ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
67.845,30
0,18%
Brent Oil
80,795
-0,62%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. SciSparc Ltd (SPRC)

  7. SciSparc Ltd (SPRC) Notícias

SPRC

SciSparc (SPRC)

SciSparc Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SPRC
DataHoraFonteTítuloCódigoCompanhia
31/05/202408:17GlobeNewswire Inc.SciSparc Secures Strategic Advantage with Grant of European PatentNASDAQ:SPRCSciSparc Ltd
11/04/202409:15GlobeNewswire Inc.SciSparc to Acquire AutoMaxNASDAQ:SPRCSciSparc Ltd
21/03/202409:58GlobeNewswire Inc.SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer ResearchNASDAQ:SPRCSciSparc Ltd
18/03/202408:29GlobeNewswire Inc.SciSparc Granted Another Patent, Strengthening its Core Technology in CanadaNASDAQ:SPRCSciSparc Ltd
14/03/202409:49GlobeNewswire Inc.SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical TrialNASDAQ:SPRCSciSparc Ltd
12/03/202409:14GlobeNewswire Inc.SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule StructureNASDAQ:SPRCSciSparc Ltd
08/03/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
08/03/202409:11GlobeNewswire Inc.SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
07/03/202409:49GlobeNewswire Inc.SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in EuropeNASDAQ:SPRCSciSparc Ltd
07/03/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SPRCSciSparc Ltd
06/03/202418:41GlobeNewswire Inc.SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management TechnologyNASDAQ:SPRCSciSparc Ltd
29/02/202410:35GlobeNewswire Inc.SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of DosingNASDAQ:SPRCSciSparc Ltd
27/02/202418:15Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:SPRCSciSparc Ltd
27/02/202409:58GlobeNewswire Inc.SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
27/02/202409:58GlobeNewswire Inc.Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
20/02/202409:14GlobeNewswire Inc.Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
20/02/202409:14GlobeNewswire Inc.SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
29/01/202409:18GlobeNewswire Inc.SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
24/01/202409:42GlobeNewswire Inc.SciSparc Ltd. Announces $20 Million Standby Equity Purchase AgreementNASDAQ:SPRCSciSparc Ltd
19/01/202411:28GlobeNewswire Inc.SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 millionNASDAQ:SPRCSciSparc Ltd
04/01/202409:18GlobeNewswire Inc.SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based TreatmentsNASDAQ:SPRCSciSparc Ltd
04/01/202409:18GlobeNewswire Inc.Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based TreatmentsNASDAQ:SPRCSciSparc Ltd
13/12/202310:18GlobeNewswire Inc.SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery PlatformNASDAQ:SPRCSciSparc Ltd
07/12/202311:05GlobeNewswire Inc.SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in IsraelNASDAQ:SPRCSciSparc Ltd
01/12/202310:14GlobeNewswire Inc.Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical TrialNASDAQ:SPRCSciSparc Ltd
28/11/202318:55Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:SPRCSciSparc Ltd
28/11/202310:55GlobeNewswire Inc.SciSparc Adopts Limited Duration Shareholder Rights PlanNASDAQ:SPRCSciSparc Ltd
28/11/202310:25GlobeNewswire Inc.SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based TreatmentNASDAQ:SPRCSciSparc Ltd
24/11/202310:55GlobeNewswire Inc.New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
22/11/202309:42GlobeNewswire Inc.SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in IsraelNASDAQ:SPRCSciSparc Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:SPRC

Seu Histórico Recente

NASDAQ
AAXGOXX
Jpmorgan Chase Financial...
BIT
UC8AMB
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados